Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation

Several typos occurred during the production process and captions were misplaced. The corrected captions for Picture 1, Fig. 6-9 are below.

[1]  Mingshi Yang,et al.  Anti-solvent Precipitation Method Coupled Electrospinning Process to Produce Poorly Water-Soluble Drug-Loaded Orodispersible Films , 2019, AAPS PharmSciTech.

[2]  Hany SM Ali,et al.  Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability , 2019, International journal of nanomedicine.

[3]  I. Ermolina,et al.  Application of Texture Analysis Technique in Formulation Development of Lyophilized Orally Disintegrating Tablets Containing Mannitol, Polyvinylpyrrolidone and Amino Acids , 2019, AAPS PharmSciTech.

[4]  Haoyang Wen,et al.  Structure-Based Gastro-Retentive and Controlled-Release Drug Delivery with Novel 3D Printing , 2019, AAPS PharmSciTech.

[5]  Shahnaz Usman,et al.  Formulation development and optimization of orally disintegrating tablets of montelukast sodium by Design- Expert , 2018, Tropical Journal of Pharmaceutical Research.

[6]  Ashok Thulluru,et al.  Quality By Design approach to optimize the taste masked Zolpidem tartrate Oral Disintegrating Tablets , 2018 .

[7]  Alptug Karakucuk,et al.  Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  B. D. Rohera,et al.  An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine , 2017, Pharmaceutical development and technology.

[9]  J. Haro,et al.  Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder , 2017, Patient preference and adherence.

[10]  Ting Chen,et al.  Fabrication and in vitro/in vivo evaluation of amorphous andrographolide nanosuspensions stabilized by d-α-tocopheryl polyethylene glycol 1000 succinate/sodium lauryl sulfate , 2017, International journal of nanomedicine.

[11]  C. Prestidge,et al.  Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  K. Kamiński,et al.  The Improvement of the Dissolution Rate of Ziprasidone Free Base from Solid Oral Formulations , 2015, AAPS PharmSciTech.

[13]  Emad B. Basalious,et al.  Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization and in vitro/in vivo studies , 2013, Pharmaceutical development and technology.

[14]  R. Conley,et al.  Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States , 2012, Journal of medical economics.

[15]  S. Stahl,et al.  Ziprasidone Hydrocloride: What Role in the Management of Schizophrenia? , 2011, Journal of central nervous system disease.

[16]  S. Baumgartner,et al.  Advantages of celecoxib nanosuspension formulation and transformation into tablets. , 2009, International journal of pharmaceutics.

[17]  L. San,et al.  Olanzapine Orally Disintegrating Tablet: A Review of Efficacy and Compliance , 2008, CNS neuroscience & therapeutics.

[18]  E. Merisko-Liversidge,et al.  Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds , 2008, Toxicologic pathology.

[19]  J. Bobes,et al.  Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  B. Kinon,et al.  Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. , 2003, The international journal of neuropsychopharmacology.

[21]  Nevin Çelebi,et al.  Ağızda Dağılan Tabletler: Genel Bakış ve Tasarımla Kalite Yaklaşımı , 2017 .

[22]  A. Rani,et al.  Formulation and In-Vitro Characterisation of Fast Disintegrating Tablets of Ziprosidone , 2013 .

[23]  Industrial Pharmacy.  APPLYING QBD APPROACH TO DEVELOP ODTS CONTAINING ACECLOFENAC SOLID DISPERSION WITH RANITIDINE HCL USING DIRECT COMPRESSION TECHNIQUE, THEN PHARMACEUTICALLY EVALUATING AND PHARMACOLOGICALLY CONFIRMING THE THERAPEUTIC ACTIONS , 2013 .

[24]  J. S. Patil,et al.  Enhancing Dissolution Rate of Ziprasidone via Co-grinding technique with highly Hydrophilic Carriers , 2012 .